AUTHORS
Emily C. Liang, MD, Alexandria Jensen, Phd2, Oren Pasvolsky, MD3, Vanna Hovanky4, Lekha Mikkilineni, MD, MA5, Omar Nadeem, MD6, Shonali Midha, MD7, Chenyu Lin, MD8, Doug W. Sborov, MD, MS9, Gliceida M Galarza Fortuna, MD10, Noa Biran, MD11, Christopher J. Ferreri, MD12, Cindy Varga, MD,BSc13, Hector Jose Garcia Pleitez, MD14, Mahmoud R. Gaballa, MD15, Sharlene Dong, MD, MS16, Aimaz Afrough, MD17, Ricardo Daniel Parrondo, MD18, Melinda Tan, MD19, Yi Lin Jr, MD, PhD20, Nadine Abdallah I, MD21, Ran Reshef, MD, MSc22, Francesca Cottini, MD23, Ashley Rosko, MD24, Sneha Purvey, MD25, Doris K. Hansen, MD26, Omar Alexis Castaneda Puglianini, MD27, Ariel Grajales-Cruz, MD28, Melissa Alsina, MD29, Taiga Nishihori, MD30, Danai Dima, MD31, Andrew J. Portuguese, MD32, Binoy Yohannan, MD33, Marcus Geer, MD34, James A Davis, PharmD, BCOP35, Megan M Herr, PhD36, Jennifer Ann Kanakry, MD37, Asya Varshavsky Yanovsky, MD, PhD38, David Oveisi I, MD39, Hitomi Hosoya, MD, PhD40, Timothy O'Brien, MD41, Karen Sweiss, PharmD42, Rahul Banerjee, MD43, Surbhi Sidana, MD44, Poy Theprungsirikul, MD45
AFFILIATIONS
1 Stanford University School of Medicine, Stanford, California, United States
2 Stanford University School of Medicine, Stanford, California, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 Stanford University School of Medicine, Stanford, California, United States
5 Stanford University School of Medicine, Stanford, California, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Duke University School of Medicine, Durham, North Carolina, United States
9 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
10 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
11 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
12 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
13 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, United States
18 Mayo Clinic, Jacksonville, Florida, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 Columbia University Irving Medical Center, New York, New York, United States
23 The Ohio State University Wexner Medical Center, James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
24 The Ohio State University Wexner Medical Center, James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
25 Virginia Commonwealth University, Richmond, Virginia, United States
26 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
27 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
28 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
29 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
30 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
31 Fred Hutchinson Cancer Center, Seattle, Washington, United States
32 Fred Hutchinson Cancer Center, Seattle, Washington, United States
33 University of Minnesota, Minneapolis, Minnesota, United States
34 University of Michigan, Ann Arbor, Michigan, United States
35 Medical University of South Carolina, Charleston, South Carolina, United States
36 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
37 MedStar Georgetown University Hospital, Washington, DC, District of Columbia, United States
38 Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
39 Cedars-Sinai Medical Center, Los Angeles, California, United States
40 Cedars-Sinai Medical Center, Los Angeles, California, United States
41 University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
42 University of Illinois Chicago, Chicago, Illinois, United States
43 Fred Hutchinson Cancer Center, Seattle, Washington, United States
44 Stanford University School of Medicine, Stanford, California, United States
45 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ABSTRACT
Background
While a significant proportion of patients (pts) achieve durable responses following cilta-cel, a subset experience early relapse, particularly those with high-risk cytogenetic abnormalities (HRCAs), functional high-risk disease, and extramedullary disease (EMD). We evaluated clinical outcomes with maintenance therapy (maintenance) following cilta-cel compared with a propensity score (PS)-matched cohort not receiving maintenance.
Methods
We conducted a multicenter analysis of 1,793 pts treated with cilta-cel from 2022-2025 at 23 US academic centers within the US Multiple Myeloma Immunotherapy Consortium. Maintenance was defined as treatment initiated 30-180 days after cilta-cel infusion in the absence of progressive disease (PD). Maintenance was initiated per physician discretion. The primary endpoint was progression-free survival (PFS) from cilta-cel infusion.
Only pts who were alive and progression-free at day 30 were included. PS matching at 3:1 was used to address treatment allocation bias. Variables included in matching were: year of infusion, age at infusion, ECOG performance status at apheresis, number of prior lines of therapy (pLOT) (1 vs ≥2), prior BCMA exposure, triple-class refractoriness, presence of 2025 IMS/IMWG HRCAs, functional high-risk status (defined as relapse within 18 months [mo] of first-line therapy), presence of EMD, pre-lymphodepletion (LD) ferritin (>400 vs ≤400 ng/mL), pre-LD bone marrow plasma cell %, pre-infusion disease status (< partial response [PR] vs ≥PR), and day 30 response after cilta-cel.
Results
Only 30 pts (2%) received maintenance, initiated at a median of 101 days (IQR, 78-133) after cilta-cel infusion. In this group, the median age at cilta-cel infusion was 61 years (range, 41-75). The median number of pLOT was 4 (range 1-11). Six pts (20%) had EMD, 24 (80%) had triple class-refractory disease, 16 (53%) had HRCAs, and 18 (60%) had functional high-risk disease. All but 1 pt received bridging therapy, with nearly half (n=14, 47%) experiencing stable disease (SD) or PD prior to cilta-cel infusion. Prior to matching, pts who received maintenance tended to be younger and have higher rates of EMD, HRCAs, and functional high-risk disease, though these differences were not statistically significant.
Pomalidomide-based (n=14, 47%) and talquetamab (n=12, 40%) were the most common maintenance regimens. Among evaluable pts (n=26), the overall response rate at day 30 after cilta-cel was 100% (stringent complete response [sCR] or CR, n=10; 38%). The median follow-up after cilta-cel infusion was 16.1 mo (IQR, 13.3-18.9). Among 14 pts with documented maintenance discontinuation, the median duration of maintenance was 91.5 days (IQR, 72.7-198.0).
PS matching resulted in excellent balance with absolute standardized mean differences < 0.1. Among matched maintenance vs no maintenance cohorts, we observed similar median PFS (median: not reached [NR] vs 26.6 mo; 1-year: 59% [95% CI, 36-76%] vs 71% [95% CI, 54-83%]; HR=1.05, 95% CI, 0.47-2.36, p=0.90), overall survival (NR vs NR; 1-year: 88% [95% CI, 64-96%] vs 85% [95% CI, 69-93%]; HR = 0.94, 95% CI, 0.32-2.74, p=0.90), and time to next treatment (NR vs 31.6 mo; HR=1.12, 95% CI, 0.49-2.58, p=0.78).
Within pts who received maintenance, 10 (33%) ultimately experienced PD, and non-relapse mortality was 0%. EMD (median: 8.6 vs NR mo; HR=5.06, p=0.005) and HRCAs (median: 9.2 vs NR mo; HR=12.2, p=0.003) were associated with significantly shorter PFS among pts who received maintenance. In contrast, we did not observe differences in PFS by presence of functional high-risk disease or achieving <CR at day 30. Subgroup analyses between maintenance and no maintenance cohorts were not conducted given the excellent covariate balance.
Conclusion
In this real-world analysis, a small proportion of pts received maintenance following cilta-cel, with varied treatment regimens. Pts selected for maintenance had high-risk disease features, and many did not achieve a response to bridging, indicating refractory disease. Maintenance was not associated with improved PFS or survival in our cohort. In pts who received maintenance, EMD and HRCAs were associated with significantly shorter PFS. Prospective trials are needed to define the role, timing, and optimal agents for maintenance after cilta-cel, particularly for pts with high-risk disease, and should evaluate therapies to which pts are not previously refractory and that have complementary mechanisms of action.
DISCLOSURES
Emily C. Liang, MD: Bristol Myers Squibb - Current holder of stock options in a privately-held company; Glass Health - Consultancy (Includes expert testimony); Glass Health - Consultancy (Includes expert testimony); Bristol Myers Squibb - Divested equity in a private or publicly-traded company in the past 24 months